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Objective: To identify clinical and genetic risk factors for interstitial lung disease (ILD) or
airway disease (AD) in patients with rheumatoid arthritis (RA) and to evaluate differences
between the associations of these factors with ILD and AD.
Methods: We reviewed high-resolution computed tomography (HRCT) images and clinical data
of 356 RA patients obtained at their first visit. The diagnosis of ILD and AD was based on
abnormal HRCT findings. Multinomial logistic regression analysis and likelihood ratio tests were
performed.
Results: High titers of rheumatoid factor are similarly associated with increased risks of ILD
(relative risk ratio, 3.1; p Z 0.02) and AD (relative risk ratio, 3.0; p Z 0.02). High levels of
anti-cyclic citrullinated peptide antibodies were associated strongly with AD (relative risk
ratio, 3.8; p Z 0.005) and less strongly with ILD (relative risk ratio, 2.7; p Z 0.07). Age was
the potent risk factor for ILD (relative risk ratio, 4.6; p Z 0.003), while that for AD was
advanced stage (relative risk ratio, 11.5; p < 0.0005). The carriage of HLA-DRB1*1502 had
opposite influences on the two conditions: relative risk ratio Z 4.02 for ILD (p Z 0.013) and
relative risk ratio Z 0.15 for AD (p Z 0.08). This difference was statistically significant
(pZ 0.0005). Associations of sex and smoking history with ILD disappeared in the multinomial
logistic regression analysis.
Conclusions: The differential associations of ILD and AD with various clinical and genetic
factors suggest that ILD and AD have distinct etiologies in RA.
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genotyping tests for HLA-DRB1 alleles at the same time.Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by a persistent synovitis of multiple joints
and systemic inflammation in extraarticular organs,
including cutaneous, ocular, hematological, cardiovascular,
neurological and pulmonary involvement. Approximately
40% of patients suffer from extraarticular manifestations at
some time during the course of their disease.1e3 The
presence of extraarticular manifestations is well recog-
nized as the strongest predictor of mortality in RA,4e6 and
the extent of systemic inflammatory involvement may be
a major determinant of survival in RA patients.7 Among the
extraarticular manifestations of RA, there has been
renewed interest in pulmonary complications directly
associated with RA, which manifest as a variety of clinical
signs such as pleural disease, pulmonary nodules, intersti-
tial lung disease (ILD), and airway disease (AD).8e10 In our
recent studies using high-resolution computed tomography
(HRCT), the incidences of ILD and bronchiolitis in RA
patients were 10e12% and 8%, respectively.11,12 A large
observational cohort study in Japan has shown that the
presence of ILD is one of the factors associated with
increased mortality in RA patients.13 Mortality is relatively
high in RA patients with pulmonary fibrosis or
bronchiectasis.14e18 Tsuchiya et al. indicated that more
than 80% of patients with RA-related pulmonary diseases
died from pulmonary complications.19
It has been reported that several factors, including
smoking history, erosive/destructive changes of joints, high
disease activity and disability, anti-cyclic citrullinated
peptide antibodies (anti-CCP Abs), rheumatoid factor (RF),
and shared epitope (SE)-positive HLA-DRB1*04 alleles,
predict severe extraarticular complications.1,3,6,20e22
Several factors associated with pulmonary complications
in RA have also been described, though these have
remained the subject of debate.23e29 In addition, no study
has yet aimed to identify respective risk factors for ILD and
AD in RA patients at the same time. It is, therefore, difficult
to examine whether some factors are more closely associ-
ated with one type of pulmonary complication than with
the other.
In the present study, we performed multinomial logistic
regression analysis to identify clinical and genetic factors
associated with the presence of ILD or AD in RA. Data ob-
tained from 356 RA patients at their first visit to our insti-
tute were used. To further evaluate whether there is
a differential association between the two pulmonary
complications and each factor, we performed likelihood
ratio tests. The contributions of individual factors to ILD
and AD were compared and discussed in the context of
pathogenesis of RA.Materials and methods
Patients and study design
The subjects of this study were 356 Japanese patients with
RA who visited our outpatient clinic between November
2009 and July 2011, and who had consented to undergoThese patients were consecutively enrolled in this
study unless they met either of the following exclusion
criteria: (1) a history of exposure to dust such as asbestos
or silica or (2) a history of thoracic radiation for cancer
therapy. Ultimately, 92% of our RA cohort participated in
this study. The patients were not selected based on their
reasons for visiting, which included evaluation of articular
symptoms, treatment consultation, RA complications,
and other reasons. Our department is organized primarily
to serve patients with early RA who are scheduled for
anti-RA therapy with biological agents and/or metho-
trexate; therefore, the proportion of patients with long-
standing RA and that of patients already receiving
such drugs as of their first visit were considerably
lower than those in the overall RA population. All partic-
ipants fulfilled the 1987 American College of Rheuma-
tology criteria for diagnosis of RA. Clinical and laboratory
data obtained at the first visit were retrospectively
examined by reviewing patients’ medical records. These
included age, disease duration, Steinbroker’s stage,
smoking history, titers of anti-CCP Ab and RF, respiratory
symptoms, and anti-RA drugs prescribed at former clinics.
The ethics committee of our hospital approved the
protocol for this study, and informed consent was obtained
from all patients.
HRCT scanning and evaluation
Patients’ HRCT images taken at their first visit were
reviewed in a blinded fashion to the patients’ clinical
status. Abnormal HRCT findings were defined according to
the criteria described in our previous report.11 For each
case, we identified one or two predominant HRCT findings.
Their distribution and extent were assessed by separately
scoring the predominant HRCT abnormalities according to
the number of pulmonary segments involved. We then
determined the probable diagnosis according to the criteria
for interpreting HRCT patterns defined by Tanaka et al.30
We classified participants into the following 3 groups:
patients with ILD (n Z 24), those with AD (n Z 30), and
those without either disease (n Z 302). The ILD group
included 19 patients with nonspecific interstitial pneu-
monia (NSIP) pattern and 5 with usual interstitial pneu-
monia (UIP) pattern. The AD group included 10 patients
with bronchiectasis pattern and 25 with bronchiolitis
pattern. Five cases in the AD group had both bronchiectasis
and bronchiolitis patterns. Only one case may be consid-
ered to represent a mixed pattern of ILD and AD, because
the patient’s HRCT revealed ground-glass attenuation,
reticulation, and parenchymal micronodules as the
predominant abnormalities. After scoring these abnormal-
ities, we finally reached a consensus that the most
predominant HRCT finding in this patient was ground-glass
attenuation. Accordingly, this patient was classified into
the ILD group (the NSIP pattern).
HLA-DRB1 genotyping
Blood samples were collected after obtaining written
informed consent, and then subjected to genotyping
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was carried out at the HLA Laboratory, NPO (Kyoto,
Japan), using polymerase chain reaction amplification
and hybridization with sequence-specific oligonucleotide
probes (PCR-SSOP method, WAKFlow HLA typing kit,
Wakunaga Pharmaceutical Company, Hiroshima, Japan).
Measurements of anti-CCP Abs and IgM RF
Sera that had been collected at each patient’s first visit and
stored at 80 C were used for the detection of anti-CCP
Abs and IgM RF. Anti-CCP Abs were measured with
a commercially available enzyme-linked immunosorbent
assay (ELISA) kit (anti-CCP2 assay, Axis-Shield
Diagnostic Limited, Dundee, Scotland) according to the
manufacturer’s instructions. A serum was considered to
be anti-CCP Ab-positive if the absorbance value was
greater than 4.6 U/ml. IgM RF was measured by nephe-
lometry; a serum was considered to be positive if the
concentration was higher than the cut-off value (15 IU/ml).
High titers of anti-CCP Abs and RF were defined as serum
concentrations 90 U/ml and 100 IU/ml, respectively,
based on the respective median values of titers of these
antibodies.
Statistical analysis
In univariate analyses of categorical variables, levels of
significance were determined by means of the chi-square
test or Fisher’s exact probability test using contingency
tables. Continuous variables were assessed using the Krus-
kaleWallis test with a post hoc Scheffe´ test.
Multinomial logistic regression analysis (also called pol-
ytomous logistic regression) was performed to assess the
relationship between the presence of ILD or AD (as
a response variable) and a set of predictor variables
including age (65), sex, advanced stage (Steinbroker’s
stage III and IV), smoking history (10 pack-years), carriage
of shared epitope (SE)-positive HLA-DRB1*04 alleles, HLA-
DRB1*1501 carriage, HLA-DRB1*1502 carriage, titers of RF
(100 IU/ml), and titers of anti-CCP Abs (90 U/ml). The
strength of association was estimated using relative risk
ratios and the 95% confidence interval (95% CI). In addition,
receiver operating characteristic (ROC) curves and the
corresponding areas under the curves (AUC) were calcu-
lated to provide an index of validity of multinomial logistic
regression models.
To further evaluate whether there is a differential
association between the two disease outcomes for each
factor, we performed likelihood ratio tests of the null
hypothesis that the relative risk ratio for ILD is equal to that
for AD, against the alternative hypothesis that the relative
risk ratio is not equal between ILD and AD. The higher the
likelihood ratio, the more likely it is that the alternative
hypothesis is true; namely, the factor is differently asso-
ciated between the two disease outcomes.
For all tests, probability values (p values) < 0.05 were
considered to indicate statistical significance. All calcula-
tions were performed using Excel Statistical Analysis 2008
(SSRI Co., Ltd., Tokyo, Japan) or Stata version 11.2 (Sta-
taCorp LP, College Station, TX, USA).Results
Clinical characteristics of RA patients with and
without pulmonary complications
Out of the 356 patients examined, 24 (6.7%) and 30 (8.4%)
patients were diagnosed with ILD and AD, respectively.
There was no evidence of drug-induced lung disease or
pulmonary infection in these patients. In the other 302
patients (84.8%), the distribution and extent of abnormal
HRCT findings were insufficient to warrant a diagnosis of
ILD or AD. As shown in Table 1, the median age of the ILD
group was significantly older than that of the patients
without pulmonary complications (p < 0.0005). In addition,
ILD was more often seen in male patients (50% versus
23.2%; OR, 3.31; p Z 0.004), those with smoking history
(45.8% versus 20.5%; OR, 3.28; p Z 0.004), those with high
titers of anti-CCP Abs (90 U/ml; 79.2% versus 47.7%; OR,
4.17; p Z 0.003), those positive for RF (95.8% versus
74.5%; OR, 7.87; p Z 0.022), and those with high titers of
RF (100 IU/ml; 70.8% versus 35.1%; OR, 4.49,
p Z 0.0005). Disease duration of patients with AD was
significantly longer than that of patients without pulmo-
nary complications (p < 0.0005). Patients with long-
standing RA more often had AD (86.7% versus 39.4%; OR,
10.0; p < 0.0005). The patients in the AD group were also
more likely to suffer from severe joint damage (86.7%
versus 32.5%; OR, 13.53; p < 0.0005). High levels of anti-
CCP Abs (90 U/ml) and RF (100 IU/ml) were also asso-
ciated with presence of AD (anti-CCP Abs, 70% versus
47.7%, OR, 2.56, p Z 0.02; RF, 56.7% versus 35.1%, OR,
2.42, p Z 0.02). The median titers of anti-CCP Abs were
significantly greater in the ILD and AD groups than in the
group without pulmonary complications (ILD group,
283.5 U/ml versus 81.1 U/ml, p Z 0.0005; AD group,
222.5 U/ml versus 81.1 U/ml, p Z 0.014). The median
titers of RF in the ILD and AD groups were also significantly
higher than that in patients without pulmonary complica-
tions (ILD group, 224.5 IU/ml versus 57.2 IU/ml,
p Z 0.0005; AD group, 140.5 IU/ml versus 57.2 IU/ml,
p Z 0.001). Patients in both groups were more likely to
complain of respiratory symptoms at their first visit than
those without pulmonary complications were (p < 0.0005).
None of the patients with ILD or AD were receiving any
biological therapy. In both patient groups, approximately
13% were being treated with methotrexate. Salazosulfa-
pyridine had been given to two patients (8.3%) in the ILD
group and two patients (6.7%) in the AD group. One patient
(4.2%) in the ILD group and seven patients (23.2%) in the AD
group had received bucillamine, but there was no signifi-
cant difference in the rates of use of these disease-
modifying antirheumatic drugs (DMARDs) between the ILD
group or the AD group and the group without either
pulmonary complication.
Distribution of HLA-DRB1 alleles in RA patients with
and without pulmonary complications
The distributions of individual HLA-DRB1 alleles are dis-
played in Table 2 according to the presence or absence of
pulmonary complications. Out of a total of 712 alleles, 323
Table 1 Clinical characteristics of RA patients with or without pulmonary complications (n Z 356).
No lung disease
(n Z 302)
Interstitial lung
disease (n Z 24)
p value* Airway
disease
(n Z 30)
p value*
Age, yrs, medians
(25th, 75th percentiles)
59.0 (52.0, 68.0) 72.5 (64.0, 76.3) <0.0005 64.5
(55.5, 70.8)
0.085
Male/female 70/232 12/12 0.004y 3/27 0.11
RA duration, yrs, medians
(25th, 75th percentiles)
0 (0, 6) 1.5 (0, 6.3) 0.57 7.5 (4, 12) <0.0005**
RA duration, early/longstanding 183/119 12/12 0.31 4/26 <0.0005yy
Stage III and IV, numbers
of patients (%)
98 (32.5) 10 (41.7) 0.36 26 (86.7) <0.0005zz
Smoking history, numbers
of patients (%)
62 (20.5) 11 (45.8) 0.004z 3 (10) 0.23
Positive anti-CCP, numbers
of patients (%)
267 (88.4) 24 (100) 0.09 27 (90) 1.00
High-titer anti-CCP
(90 U/ml), numbers
of patients (%)
144 (47.7) 19 (79.2) 0.003x 21 (70) 0.020xx
Anti-CCP titer, U/ml,
medians (25th, 75th
percentiles)
81.1 (21.0, 249.0) 283.5 (99.0, 794.0) 0.0005 222.5
(85.0, 594.0)
0.014
Positive RF, numbers
of patients (%)
225 (74.5) 23 (95.8) 0.022{ 26 (86.7) 0.18
High-titer RF (100 IU/ml),
numbers of patients (%)
106 (35.1) 17 (70.8) 0.0005# 17 (56.7) 0.020
RF titer, IU/ml, medians
(25th, 75th percentiles)
57.2 (14.3, 138.8) 224.5 (65.0, 405.0) 0.0005 140.5
(44.0, 475.3)
0.001
Respiratory symptoms,
numbers of patients (%)
0 8 (33.3) <0.0005 22 (73.3) <0.0005
Sjo¨gren’s syndrome,
numbers of patients (%)
7 (2.3) 1 (4.2) 0.46 0 1.00
Use of anti-RA drugs,
numbers of patients (%)
Anti-TNFa agents 1 (0.3) 0 1.00 0 1.00
Tocilizumab 1 (0.3) 0 1.00 0 1.00
Methotrexate 37 (12.3) 3 (12.5) 1.00 4 (13.3) 0.78
Bucillamine 38 (12.5) 1 (4.2) 0.33 7 (23.2) 0.10
Salazosulfapyridine 19 (6.3) 2 (8.3) 0.66 2 (6.7) 1.00
Data were obtained at each patient’s first visit.
Smoking history is defined as positive for current or former smokers with a smoking history 10 pack-years. One pack-year is defined as
20 manufactured cigarettes (one pack) smoked per day for 1 year.
Patients with early RA were defined as those who had been diagnosed within 2 years.
*p values are based on comparison with patients without either interstitial lung disease or airway disease.
Significance was determined by means of the chi-square or Fisher’s exact test for categorical variables and the KruskaleWallis test with
a post hoc Scheffe´ test for continuous variables. Odds ratios (95% confidence intervals) were 3.31 (1.43e7.79)y, 3.28 (1.40e7.66)z, 4.17
(1.52e11.46)x, 7.87 (1.05e59.26){, 4.49 (1.81e11.17)#, 10.00 (3.40e19.37)**, 13.53 (4.60e39.84)yy, 2.56 (1.14e5.77)zz, and 2.42
(1.13e5.17)xx, respectively.
RA, rheumatoid arthritis; anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; anti-TNFa, anti-tumor necrosis
factor-a.
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positive *04 alleles. The incidence of AD was greater in RA
patients carrying the SE-positive *04 alleles (OR, 2.20;
p Z 0.003, pc Z 0.09). ILD occurred more often in RA
patients with carriage of HLA-DRB1*1501 (OR, 3.31,
p Z 0.009, pc Z 0.27). There was a trend toward a higher
frequency of HLA-DRB*1502 in the ILD group (OR, 2.48,
p Z 0.03, pc Z 0.9).Risk factors for ILD and AD in RA patients
Multinomial logistic regression analysis indicated a strong
association of ILD with age (65; relative risk ratio, 4.58;
p Z 0.003), titers of RF (100 IU/ml; relative risk ratio,
3.14; p Z 0.023), and the carriage of HLA-DRB1*1502
(relative risk ratio, 4.02; p Z 0.013) (Table 3). Titers of
anti-CCP (Abs  90 U/ml) likewise showed a trend toward
Table 2 Distribution of HLA-DRB1 alleles in RA patients with or without pulmonary complications (n Z 712).
HLA-DRB1 alleles No lung disease
(n Z 604)
Interstitial lung
disease (n Z 48)
Airway disease
(n Z 60)
SE-positive alleles
*0101 51 (8.4) 4 (8.3) 3 (5.0)
*0401 18 (3.0) 2 (4.2) 3 (5.0)
*0405 175 (29.0) 7 (14.6)y 25 (41.7)y
*0410 13 (2.2) 3 (6.3) 4 (6.7)
*1001 8 (1.3) 1 (2.1) 0
*1406 6 (1.0) 0 0
SE-positive *04 206 (34.1) 12 (25) 32 (53.3)z
Total 271 (44.9) 17 (35.4) 35 (58.3)y
SE-negative alleles
*0301 1 (0.2) 0 0
*0302 1 (0.2) 0 0
*0403 7 (1.2) 0 1 (1.7)
*0406 9 (1.5) 1 (2.1) 2 (3.3)
*0501 2 (0.3) 0 0
*0601 1 (0.2) 0 0
*0701 3 (0.5) 0 0
*0802 7 (1.2) 1 (2.1) 1 (1.7)
*0803 21 (3.5) 3 (4.2) 3 (5)
*0901 117 (19.4) 6 (12.5) 8 (13.3)
*1101 5 (0.8) 0 1 (1.7)
*1201 22 (3.6) 2 (2.4) 2 (3.3)
*1202 10 (1.7) 1 (2.1) 0
*1301 2 (0.3) 0 0
*1302 19 (3.1) 0 1 (1.7)
*1401 11 (1.8) 1 (2.1) 4 (6.7)y
*1403 13 (2.2) 1 (2.1) 1 (1.7)
*1405 6 (1.0) 1 (2.1) 0
*1407 2 (0.3) 0 0
*1501 25 (4.1) 6 (8.3)z 0
*1502 45 (7.5) 8 (16.7)y 1 (1.7)
*1602 4 (0.7) 0 0
Total 333 (55.1) 31 (64.6) 25 (41.7)y
Data are numbers of alleles (%).
yp < 0.05, zp < 0.01. After the p values were corrected for multiple testing based on the number of comparisons made (30 comparisons,
Bonferroni correction), however, these values were >0.05.
Odds ratios (95% confidence intervals) were calculated in comparison against all other patient groups.
*0405 for ILD, 0.42 (0.18e0.95, p Z 0.032); *0405 for airway disease, 1.75 (1.02e3.01, p Z 0.041); SE-positive *04 alleles for airway
disease, 2.20 (1.29e3.77, pZ 0.003); SE-positive alleles for airway disease, 1.72 (1.00e2.95, pZ 0.046); *1401 for airway disease, 3.85
(1.19e12.49, pZ 0.039); *1501 for ILD, 3.31 (1.29e8.51, pZ 0.009); *1502 for ILD, 2.48 (1.10e5.63, pZ 0.025); SE-negative alleles for
airway disease, 0.58 (0.34e1.00, p Z 0.046).
RA, rheumatoid arthritis; SE, shared epitope; ILD, interstitial lung disease.
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Sex and smoking history were significantly associated with
ILD in the univariate analysis (Table 1), but these associa-
tions disappeared in the multinomial logistic regression
model. The presence of AD was strongly associated with
Steinbroker’s stage (III and IV; relative risk ratio, 11.48;
p < 0.0005), titers of anti-CCP Abs (90 U/ml; relative risk
ratio, 3.84; p Z 0.005), and titers of RF (100 IU/ml;
relative risk ratio, 2.96; p Z 0.016). The carriage of HLA-
DRB1*1502 showed a trend toward a negative association
with AD (relative risk ratio, 0.15; pZ 0.08). The ROC curve
showed that the final model for predicting pulmonary
complications was moderately accurate. The ROC-AUC
values for ILD versus no pulmonary disease, AD versus nopulmonary disease, and ILD or AD versus no pulmonary
disease were 0.85 (95% CI, 0.78e0.92, p < 0.0005); 0.88
(95% CI, 0.81e0.95, p < 0.0005); and 0.83 (95% CI,
0.77e0.89, p < 0.0005), respectively.Differential associations between ILD and AD for
each clinical and genetic factor
Likelihood ratio tests show that there are differential
associations between ILD and AD for three predictor vari-
ables (Table 4). The presence of the HLA-DRB1*1501 allele
was positively associated with ILD and negatively associ-
ated with AD: relative risk ratio Z 2.67 for ILD (p Z 0.16)
Table 3 Predictive factors for pulmonary complications of
RA in the multinomial logistic regression model.
Disease outcomes Relative risk ratio
(95% CI)
p
No pulmonary
complications
(Base outcome) e
Interstitial lung disease
Age (65) 4.58 (1.67e12.53) 0.003
Sex 1.45 (0.36e5.84) 0.60
Stage (III and IV) 1.57 (0.59e4.19) 0.37
Smoking history 2.50 (0.62e10.09) 0.20
Anti-CCP titers
(90 U/ml)
2.73 (0.91e8.23) 0.074
RF titers
(100 IU/ml)
3.14 (1.17e8.42) 0.023
Carriage of
SE-positive *04
0.76 (0.29e2.01) 0.58
Carriage of *1501 2.67 (0.68e10.54) 0.16
Carriage of *1502 4.02 (1.34e12.05) 0.013
Airway disease
Age (65) 1.53 (0.63e3.70) 0.35
Sex 0.34 (0.06e1.83) 0.21
Stage (III and IV) 11.48 (3.68e35.75) <0.0005
Smoking history 0.80 (0.15e4.38) 0.80
Anti-CCP titers
(90 U/ml)
3.84 (1.50e9.84) 0.005
RF titers
(100 IU/ml)
2.96 (1.23e7.13) 0.016
Carriage of
SE-positive *04
1.89 (0.68e5.21) 0.22
Carriage of *1501y 2.88  107 e
Carriage of *1502 0.15 (0.02e1.25) 0.08
In the multinomial logistic regression analysis, age (65), sex,
smoking history (10 pack-years), advanced stage (Stein-
broker’s stage III and IV), carriage of SE-positive *04, *1501
carriage, *1502 carriage, titers of rheumatoid factor (RF,
100 IU/ml), and titers of anti-cyclic citrullinated antibodies
(anti-CCP Abs,  90 U/ml) were entered as the predictor vari-
ables (independent variables). yBecause of the zero count of *
1501 alleles in the airway disease group (Table 2), the regres-
sion coefficient could not be estimated accurately.
The regression coefficients were actually computed by a soft-
ware program in terms of ln relative risk ratio, and the
regression coefficient was reported in terms of relative risk
ratio as approximately zero (2.88  107). In addition, the
likelihood ratio test showed that the upper 95% confidence limit
is 0.79.
RA, rheumatoid arthritis; anti-CCP, anti-cyclic citrullinated
peptide antibodies; RF, rheumatoid factor; SE, shared epitope;
95% CI, 95% confidence interval.
Table 4 Differential associations between interstitial
lung disease and airway disease for various factors in RA
patients.
Factors Likelihood
ratios
p
Age (65) 2.86 0.09
Sex 1.90 0.17
Stage (III and IV) 7.96 0.005
Smoking history 1.12 0.29
Anti-CCP titers (90 U/ml) 0.22 0.64
RF titers (100 IU/ml) 0.01 0.93
Carriage of SE-positive *04 1.78 0.18
Carriage of *1501 7.20 0.007
Carriage of *1502 11.97 0.0005
To determine whether relative risk ratios for ILD are equal to
those for airway disease, we performed likelihood ratio tests.
The associations of HLA-DRB1*1501, *1502, and stage (III and IV)
with the two pulmonary complications were different at the 5%
level. The higher the likelihood ratio, the more likely it is that
the factor is associated differently with ILD and airway disease.
RA, rheumatoid arthritis; anti-CCP, anti-cyclic citrullinated
peptide antibodies; RF, rheumatoid factor; SE, shared epitope;
ILD, interstitial lung disease.
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limit Z 0.79). Thus the carriage of HLA-DRB1*1501 had
opposite influences on the two pulmonary manifestations.
The difference between the relative risk ratios for ILD and
AD was statistically significant (pZ 0.007). The carriage of
HLA-DRB1*1502 likewise had opposite influences on the two
diseases: relative risk ratio Z 4.02 for ILD (p Z 0.013) and
relative risk ratioZ 0.15 for AD (pZ 0.08). The difference
between the relative risk ratios for ILD and AD wasstatistically significant (p Z 0.0005). Advanced stage RA
(stage III and IV) was positively associated with both
pulmonary manifestations, but the association was stronger
for AD than for ILD: relative risk ratio Z 1.57 for ILD
(p Z 0.37) and relative risk ratio Z 11.5 for AD
(p < 0.0005). The difference between the relative risk
ratios for ILD and AD was statistically significant
(p Z 0.005).Discussion
HLA-DRB1*15 alleles, which correspond to the HLA-DR2
serotype, are SE-negative and infrequent in RA patients.
In the present study, HLA-DRB1*1502 was associated with an
increased risk of ILD in RA. Migita et al. also observed
a significant association of HLA-DRB1*1502 with pulmonary
fibrosis in Japanese RA patients.31 These findings show that,
although HLA-DRB1*1502 does not confer susceptibility to
RA, this allele is likely to be a critical determinant of ILD.
Most recently, Furukawa et al. showed that RA patients
carrying DR2 serology (HLADRB1*15 and 16 alleles) are at an
increased risk of ILD.32 Mattey et al. showed that secondary
Sjogren’s syndrome is associated with an increased
frequency of HLA-DRB1*15 in Spanish patients with sero-
positive RA.33 Tokunaga et al. reported an association
between HLA-DRB1*15 and renal involvement in Japanese
RA patients.34 Our findings and others’ strongly suggest the
possibility that the carriage of HLA-DRB1*15 alleles may be
associated with the presence of various extraarticular
manifestations in RA patients. Of note, we have found that
the carriage of HLA-DRB1*1501 and that of *1502 had
opposite influences on the incidences of the two pulmonary
manifestations examined in this study; in other words, each
of these alleles may function as a risk factor for ILD and
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for ILD and AD seem to be different. Most recently, Gyetvai
et al. suggested that HLA-DRB1*15 alleles may confer
a special predisposition for the production of anti-
citrullinated fibrinogen antibody.35 In the present study,
however, there was no significant difference in median
titers of anti-CCP Abs between carriers and non-carriers of
HLA-DRB1*1502 (*1502 carriers, 116 U/ml; *1502 non-
carriers, 96 U/ml, p Z 0.67). The association of the HLA-
DRB1*1502 allele with ILD in RA patients cannot be
completely explained by the production of anti-CCP Abs.
Many of the gene products of HLA-DRB1*01 and *04 are
known to contain the SE motif in the third hypervariable
chain of HLA-DRB1, which is a major genetic element
conveying susceptibility to RA.36,37 In some studies,
carriage of the HLA-DR4 type, a serotype recognizing the
DRB1*04 gene product, was significantly associated with the
presence of obstructive lung disease/small airway
obstruction25,26 and obliterative bronchiolitis.27 An associ-
ation of obliterative bronchiolitis with the HLA-DR1 type,
a serotype recognizing the DRB1*01 gene product, has also
been reported.27 In contrast, other groups have indicated
that none of the HLA-DR4 subtypes was unusually common
in RA patients with pulmonary involvement including
pulmonary fibrosis, small airway obstruction, or bronchi-
ectasis.28,29 Most recently, Migita et al. showed that the
frequency of SE-positive alleles in Japanese RA patients
with pulmonary fibrosis is not significantly different from
that in patients without this complication.31 In the present
study, likewise, we have found, using multinomial logistic
regression analysis, that the carriage of SE-positive *04
alleles is not a risk factor for either ILD or AD. This
discrepancy may be explained by variation in definitions of
lung disease and patient selection. A number of studies
have suggested that SE-positive HLA-DRB1 alleles are
associated with a more severe disease course characterized
by a greater frequency of extraarticular manifestations and
erosive joint destruction.38,39 Previously, we reported that
SE-positive *04 alleles are the strongest predictors for the
development of DMARD resistance in patients with early
RA.40 Nevertheless, pulmonary involvement in RA patients
appears to be associated with genetic backgrounds other
than SE-positive alleles.
Anti-CCP Abs have been considered highly specific
diagnostic markers41,42 as well as predictive factors in
terms of radiological damage and DMARD resistance early in
the disease course.40,43e45 In the present study, there was
no difference in the positive rate of anti-CCP Abs between
patients with ILD and those with AD, but serum levels of
these antibodies were significantly increased in patients
with pulmonary disease, particularly in those with AD.
Currently, there are only a few reports showing an associ-
ation between levels of anti-CCP Abs and pulmonary
disease in RA patients. Alexiou et al. reported an associa-
tion of high levels of serum anti-CCP Abs with pulmonary
fibrosis in Greek RA patients.23 Aubart et al., using multi-
variate logistic regression analysis, indicated that increased
levels of anti-CCP Abs are associated with co-occurrence of
pulmonary diseases such as ILD, bronchiectasis, and rheu-
matoid nodules in French RA patients.24 Recently, it has
been proposed that the lung is a production site for cit-
rullinated proteins by peptidylarginine deiminases.46,47Some of these proteins may trigger immune responses in
the lung and finally result in high titers of antibodies to
citrullinated protein antigens. It is not clear whether these
antibodies contribute to the initiation of pulmonary
diseases in RA patients or whether they merely reflect
ongoing pulmonary injury.
In the present study, advanced stage was found to be the
strongest risk factor for AD. When disease duration (>10
years) was entered as one of the independent variables in
place of advanced stage, it was also strongly associated
with AD. We have previously indicated that bronchiolar
abnormalities on HRCT scans are more prominent in
patients with longstanding RA, though there was no signif-
icant difference in the frequency of interstitial abnormal-
ities between patients with early RA and those with
longstanding RA.11 In another study, we found that longer
disease duration (>10 years) is a strong risk factor for small
airway dysfunction defined as abnormal forced expiratory
flow from 25% to 75% of vital capacity value (FEF25e75).
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Thus patients with longstanding and advanced-stage RA
are considered to be predisposed to bronchial and bron-
chiolar abnormalities.
The main limitation of the present study is its sample
size, which resulted in a relatively small number of patients
with each RA-associated pulmonary disease. This may
produce false-positive results or lead us to overestimate
the magnitude of an association. Further confirmatory
studies with larger sample sizes should be conducted to
justify our conclusions. In addition, the design of the
present study was of the cross-sectional descriptive type,
which may confer certain inherent limitations on the study.
Namely, this type of study cannot be used to determine
causal relationships. Longitudinal follow-up studies are
therefore required to demonstrate any cause-and-effect
relationships between RA-related pulmonary diseases and
the clinical and genetical factors identified in this study.
The ILD and AD groups are heterogeneous within
themselves.8e10 In the present study, the former included
patients with UIP and NSIP patterns, and the latter con-
sisted of patients with bronchiolitis and bronchiectasis
patterns. These conditions are reported to cause signifi-
cantly different prognoses during the course of RA19,48,49;
therefore, it may be important to evaluate the risk
factor(s) for each subgroup. The further division of the ILD
and AD groups into these subgroups, however, results in
even smaller numbers of patients in each subgroup, which
may reduce statistical power. Furthermore, considerable
overlap in HRCT features exists between NSIP and UIP,30,50
making it difficult to discriminate the UIP pattern from the
fibrotic NSIP pattern in some patients, although in most
patients the classification based on HRCT features accu-
rately reflects histopathological features. For definitive
diagnosis of these complications, lung biopsy may be
required.48,51 Pulmonary function tests (PFTs) may have
been necessary for more precise diagnosis of pulmonary
diseases. We previously found that PFT findings are well
correlated with HRCT-based diagnosis, and that, at the
same time, obstructive dysfunction of small airways,
defined as an FEF25e75 value >1.96 residual standard devi-
ation below predictive values, is apparently common
among RA patients, even among those with neither the ILD
nor the bronchiolitis pattern on HRCT scans.12 In this study,
1598 S. Mori et al.therefore, we classified our patients through HRCT-based
diagnosis.
Despite these limitations, we believe that the present
study also has several advantages. One advantage of our
methodological approach is that the diagnosis of patients’
lung disease was made based upon HRCT images taken at
their first visit. It has been reported that the use of
DMARDs may be associated with an increased risk of lung
disease in RA patients.9 It may be difficult to determine
whether such an association, if one exists, is drug-related
or simply reflective of the severity and/or duration of RA,
because patients with longstanding and/or advanced-stage
RA tend to have received more DMARDs for longer dura-
tions. In the present study, however, only two patients
(0.6%) had received biological agents prior to data acqui-
sition. Methotrexate, bucillamine, and salazosulfapyridine
had been prescribed for 12.4%, 12.9%, and 6.5% of
patients, respectively, and the proportions of users of
these drugs were similar between the ILD and AD groups
and the group without either pulmonary complication.
Leflunomide had been used for only one patient in the
group without ILD or AD. None of the patients in the
current study had been treated with penicillamine or gold.
Thus we can say that the influence of anti-RA drugs seems
to have been very low in the present study. Recent large-
scale studies have also shown that a causal association
between use of DMARDs and serious ILD in RA is weak and
even unclear.52,53
Another advantage is the utilization of multinomial
logistic regression analysis, which can include both types of
pulmonary complications (ILD and AD) as response variables
at the same time. A single multinomial logistic regression
model has certain advantages over two separate binomial
logistic regression models, including (1) the fact that the
analysis was performed on a single sample (better gener-
alizability), (2) the fact that all of the data are used at once
(increased statistical power), (3) the fact that the sum of
probability of being in one of the three states is constrained
to 100%, and (4) the ability to determine whether some
factors are more closely associated with one type of
pulmonary complication than with the other. In addition,
the likelihood ratio test made it possible to prove a differ-
ential association between the two pulmonary complica-
tions for each factor.
In conclusion, we have found that high titers of RF and
anti-CCP Abs are associated with the presence of ILD and
AD. Age was the potent risk factor for ILD, but not for AD;
advanced stage was the factor most strongly associated
with AD. The carriage of HLA-DRB1*1502 had opposite
influences on the incidences of the two pulmonary mani-
festations. The differential associations of ILD and AD with
various clinical and genetic factors suggest that ILD and AD
have distinct etiologies in RA patients. Further large-scale,
longitudinal studies are encouraged to verify this fasci-
nating discovery about the pathogenesis of RA-related lung
disease.Funding
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